论文部分内容阅读
慢性乙型肝炎感染是一个全球性的健康问题。临床过程比较复杂,积极的预防和治疗十分重要。免疫接种是预防乙肝病毒感染最有效的措施。目前临床治疗药物有干扰素、拉米夫定和阿德福韦。根据患者病情发展进程不同(非活动性乙肝病毒携带者、病毒复制期的乙肝病毒感染、代偿性或失代偿性肝脏疾病、肝硬化)分别进行药物治疗或手术治疗,且从血清学、生化学、组织学、病毒学角度评价乙肝药物的治疗效果。
Chronic hepatitis B infection is a global health problem. The clinical course is more complicated, and active prevention and treatment are very important. Immunization is the most effective measure to prevent hepatitis B virus infection. The current clinical treatment of interferon drugs, lamivudine and adefovir. According to patients with different disease progression (inactive hepatitis B virus carriers, hepatitis B virus replication during replication, compensatory or decompensated liver disease, cirrhosis) were treated with drugs or surgery, and from the serological, Biochemistry, histology, virology evaluation of the therapeutic effect of hepatitis B drugs.